Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TARGINIQ vs CO-GESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
FDA-approved: Management of severe chronic pain requiring daily around-the-clock opioid treatment, in patients who have responded to and tolerated oxycodone and require treatment for opioid-induced constipation.,Off-label: Not specified
FDA: Management of moderate to moderately severe pain where an opioid is appropriate.,Off-label: Not commonly used off-label; may be considered for refractory pain conditions.
1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
Oxycodone terminal half-life is 3.5-4.0 hours; naloxone half-life is 1-1.5 hours. The prolonged-release formulation yields a longer apparent half-life, supporting twice-daily dosing.
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Oxycodone: primarily hepatic via CYP3A4 and CYP2D6. Naloxegol: primarily hepatic via CYP3A4.
Hydrocodone: primarily hepatic via CYP3A4-mediated N-demethylation to norhydrocodone (active) and O-demethylation via CYP2D6 to hydromorphone (active). Acetaminophen: hepatic via glucuronidation and sulfation; minor oxidation by CYP2E1 to NAPQI (toxic metabolite).
Oxycodone is primarily excreted renally as noroxycodone and free oxycodone; naloxone undergoes extensive hepatic metabolism and is excreted renally as naloxone-3-glucuronide. For TARGINIQ, approximately 87% of the dose is eliminated in urine: 19% as unchanged oxycodone, 1% as unchanged naloxone, and the remainder as metabolites. Fecal excretion accounts for ~10%.
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Oxycodone: 45% bound primarily to albumin. Naloxone: approximately 40% bound predominantly to albumin.
<20%; primarily binds to albumin.
Oxycodone: Vd 2.6 L/kg, indicating extensive tissue distribution. Naloxone: Vd 2.1 L/kg.
1.2–1.9 L/kg; suggests extensive distribution into total body water.
Oral bioavailability of oxycodone: 60-87% (first-pass metabolism). Naloxone oral bioavailability: <2% due to extensive first-pass hepatic metabolism, allowing local gastrointestinal effect without significant systemic opioid antagonism.
Oral: 85–95%; rectal: 70–80%.
For GFR <60 m L/min: initiate at 50% of usual dose and titrate cautiously. For GFR <30 m L/min: consider alternative therapy; if used, reduce starting dose by 50% and monitor closely. Not recommended in end-stage renal disease (GFR <15 m L/min).
GFR 30-59 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8 hours; GFR <10 m L/min: Administer every 12 hours; avoid use in severe renal impairment.
Child-Pugh Class A: no adjustment required. Child-Pugh Class B: initiate at 50% of usual dose and titrate cautiously. Child-Pugh Class C: contraindicated due to risk of naloxone accumulation and CNS effects.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; Child-Pugh Class C: Use not recommended due to hepatotoxicity risk.
Not recommended for use in pediatric patients (≤18 years) due to lack of safety and efficacy data.
Children ≥2 years: Hydrocodone 0.1-0.2 mg/kg/dose (max 5 mg/dose) plus acetaminophen 10-15 mg/kg/dose (max 500 mg/dose) orally every 4-6 hours as needed; maximum 5 doses per day.
Initiate at the lower end of the dosing range (e.g., 1 tablet every 12 hours) and titrate cautiously. Monitor for signs of CNS depression, constipation, and respiratory depression. Consider baseline renal and hepatic function for dose adjustments.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours) due to increased sensitivity to opioids and renal clearance decline; monitor for respiratory depression and sedation.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of even one dose of TARGINIQ, especially by children, can cause fatal respiratory depression; neonatal opioid withdrawal syndrome; opioid-induced hyperalgesia and allodynia; concomitant use with CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may increase naloxegol exposure and risk of adverse reactions.
Risk of addiction, abuse, and misuse; serious, life-threatening or fatal respiratory depression from opioid use; accidental ingestion of acetaminophen can cause acute liver failure; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Opioid-induced hyperalgesia and allodynia,CYP3A4 inhibitor/inducer interactions with naloxegol,Gastrointestinal obstruction: naloxegol is contraindicated in patients with known or suspected gastrointestinal obstruction,Risk of severe opioid withdrawal symptoms with abrupt discontinuation or naloxegol dose increase
Addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risk with concomitant use of CNS depressants; severe hypotension; seizures; serotonin syndrome; adrenal insufficiency; hepatotoxicity (acetaminophen overdose); hypersensitivity reactions; constipation; urinary retention; impaired mental/physical abilities.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction,Concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with naloxegol,Hypersensitivity to oxycodone, naloxegol, or any component of the formulation
Hypersensitivity to hydrocodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction (e.g., paralytic ileus); use of MAO inhibitors (concurrent or within 14 days).
Take on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid grapefruit juice and other CYP3A4 inhibitors in food, as they may increase naloxegol levels.
Avoid grapefruit and grapefruit juice as they may alter metabolism of hydrocodone. Take with food if gastrointestinal upset occurs. Avoid alcohol-containing foods or beverages. No other significant food interactions.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal at birth.
First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductus arteriosus and oligohydramnios.
Oxycodone and naloxone are excreted in breast milk. Oxycodone M/P ratio approximately 3.2. Use with caution; monitor infant for respiratory depression and sedation. Consider risk of infant opioid exposure.
No data on M/P ratio; use with caution. Low molecular weight may be excreted into breast milk; monitor infant for sedation or respiratory depression.
Pregnancy may increase clearance of oxycodone; dose adjustments may be required. However, no specific guidelines. Use lowest effective dose; avoid prolonged use. Taper if discontinuing to prevent withdrawal.
No specific dose adjustments required; however, due to increased renal clearance in pregnancy, shortened dosing intervals or higher doses may be needed for adequate analgesia. Monitor clinical response and adjust accordingly.
TARGINIQ (naloxegol) is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It does not cross the blood-brain barrier, so it does not reverse central analgesia or precipitate opioid withdrawal. Contraindicated in patients with known or suspected gastrointestinal obstruction. Administer on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) as they increase naloxegol exposure. Dose adjustments needed for moderate or severe hepatic impairment.
Co-Gesic is a fixed-dose combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g. Hydrocodone is a Schedule II controlled substance with abuse potential. Use with caution in patients with respiratory compromise, COPD, or sleep apnea. Avoid concurrent use with other CNS depressants including alcohol. In opioid-tolerant patients, withdrawal may occur if discontinued abruptly.
Take TARGINIQ on an empty stomach, at least 1 hour before or 2 hours after eating.,Do not crush or chew the tablet; swallow it whole with water.,If you miss a dose, skip it and take the next dose at the regular time. Do not take two doses at once.,Common side effects include abdominal pain, diarrhea, nausea, gas, and headache. Call your doctor if you have severe or persistent symptoms.,Seek immediate medical attention if you have severe stomach pain, vomiting, or if you are unable to pass stool (possible bowel obstruction).,Inform your doctor about all medications you take, especially strong CYP3A4 inhibitors like certain antibiotics or antifungals.,TARGINIQ does not affect the pain relief from your opioid medication; continue taking your pain medicine as prescribed.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol while taking this medication due to risk of liver damage and increased sedation.,Do not take other medications containing acetaminophen (Tylenol, many cold/flu products) to avoid exceeding the maximum daily dose (4 grams).,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of children and dispose of unused medication properly (take-back programs preferred).,Do not crush or chew extended-release formulations (if applicable).,Report signs of liver injury (yellowing skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TARGINIQ vs CO-GESIC, answered by our medical review team.
TARGINIQ is a Opioid Analgesic Combination that works by TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.. CO-GESIC is a Opioid Analgesic Combination that works by CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TARGINIQ and CO-GESIC depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TARGINIQ is: 1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.. The standard adult dose of CO-GESIC is: 1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TARGINIQ and CO-GESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TARGINIQ is classified as Category C. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube. CO-GESIC is classified as Category C. First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.